“The quality and coverage of B2B contact database are very impressive...”
Mark J.
`
Create an account and get access to all information about Altimmune, Inc
No Credit card required. Free Credit
No Credit card required. It’s fast, easy, and FREE! 🛠️
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
“The quality and coverage of B2B contact database are very impressive...”
Mark J.
About
Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The companys lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcellTM, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B
| C-Level 3 | VP - Level6 |
| Director18 | Manager11 |
| Others25 | |
| Structure | Email Format |
|---|---|
| <f><last>@ |
|
| <first>@ | John@altimmune.com |
| <last>@ | Smith@altimmune.com |
| <first><last>@ | JohnSmith@altimmune.com |
Altimmune, Inc looking to hire in Desktop Publishing in Gaithersburg, MD
Altimmune, Inc looking to hire in Digital Transformation in Gaithersburg, MD
Altimmune, Inc looking to hire in Testing in Gaithersburg, MD
Gcp
Google analytics
Access
Acrobat
Android
Archival
Archiving
Audit
Communication
Compliance
NEW YORK CITY, NY / ACCESS Newswire / October 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune,
Read MoreNEW YORK CITY, NY / ACCESS Newswire / October 5, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune,
Read MoreNEW YORK CITY, NY / ACCESS Newswire / October 4, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Altimmune,
Read MoreNEW YORK, NY / ACCESS Newswire / September 28, 2025 / If you suffered a loss on your Altimmune, Inc. (NASDAQ:ALT) investment and want to learn about a
Read MoreAltimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The companys lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcellTM, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B
Altimmune, inc operates in the Biotechnology research industry.
Altimmune, inc's revenue is $20.00k
Altimmune, inc has 51 - 200 employees.
Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.
Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.
Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.